# Erasca, Inc.

Type: Company (ERAS)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/erasca-inc
Canonical HTML page: https://getbiobrief.com/entity/erasca-inc

## Recent coverage (1 stories)

### Erasca's Pan-RAS Drug ERAS-0015 Hit by IP War, Patient Death, $2.8B Loss
2026-06-16 14:03:32 · Sentiment: Strongly negative · Impact: 7/10 · Sources: 2

Revolution Medicines' patent infringement claim and a patient death have derailed Erasca's lead candidate, cutting its valuation by $2.8B. The biotech now faces a class action over alleged misrepresentations.
Full story: https://getbiobrief.com/story/erasca-eras-0015-ip-death-2-8b-lawsuit

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.